{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-07-11T08:53:47.371148+00:00","company":{"ticker":"ASTH","cik":1083446,"company_name":"Astrana Health, Inc."},"pagination":{"limit":100,"returned":53,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","counterparties":{"contract_counterparty":[{"display_name":"Allied Physicians of California, a Professional Medical Corporation","detail":"equity_purchase","count":1,"first_seen":"2023-11-07T23:59:59+00:00","last_seen":"2023-11-07T23:59:59+00:00","evidence_fact_ids":[97620]},{"display_name":"Community Family Care Medical Group IPA, Inc.","detail":"asset_purchase","count":1,"first_seen":"2023-11-07T23:59:59+00:00","last_seen":"2023-11-07T23:59:59+00:00","evidence_fact_ids":[97618]},{"display_name":"Ronald Brandt and Allison Brandt","detail":"equity_purchase","count":1,"first_seen":"2023-11-07T23:59:59+00:00","last_seen":"2023-11-07T23:59:59+00:00","evidence_fact_ids":[97619]},{"display_name":"Truist Bank","detail":"credit_facility","count":1,"first_seen":"2023-09-08T23:59:59+00:00","last_seen":"2023-09-08T23:59:59+00:00","evidence_fact_ids":[114519]},{"display_name":"Truist Bank, as administrative agent, and the banks and other financial institutions party thereto","detail":"credit_facility","count":1,"first_seen":"2023-11-07T23:59:59+00:00","last_seen":"2023-11-07T23:59:59+00:00","evidence_fact_ids":[97621]}],"lender":[{"display_name":"Truist Bank","detail":"term_loan","count":4,"first_seen":"2023-11-07T23:59:59+00:00","last_seen":"2025-02-27T23:59:59+00:00","evidence_fact_ids":[97622,97623,140498,140500]}],"ma_counterparty":[{"display_name":"PHP Holdings, LLC","detail":"acquisition","count":1,"first_seen":"2025-07-02T23:59:59+00:00","last_seen":"2025-07-02T23:59:59+00:00","evidence_fact_ids":[28329]}]},"facts":[{"fact_type":"shareholder_vote","fact_key":"b34c30f45e1105e61640810c2d80611bc26d592c","cik":1083446,"ticker":"ASTH","company_name":"Astrana Health, Inc.","filed_at":"2026-06-10T20:15:42+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-06-10","outcome":"passed","proposal_text":"Approval of the 2024 Plan.","proposal_type":"equity_plan","results":[{"broker_non_votes":"8,356,118","subject":null,"votes_abstain":"35,295","votes_against":"701,303","votes_for":"34,679,879","votes_withheld":null}]},"claim":"Astrana Health, Inc. shareholders approved Approval of the 2024 Plan. at the 2026-06-10 meeting.","evidence_excerpt":"Proposal 4. Approval of the 2024 Plan For Against Abstain Broker Non-Votes 34,679,879 701,303 35,295 8,356,118","confidence":0.99,"filing_url":"https://secwatch.observer/filing/0001104659-26-072343","anchor_url":"https://secwatch.observer/filing/0001104659-26-072343#claim-b34c30f45e1105e61640810c2d80611bc26d592c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1083446/000110465926072343/0001104659-26-072343-index.htm"},{"fact_type":"shareholder_vote","fact_key":"b46410f7c855fe5975ef3638942e2f37d5f13b31","cik":1083446,"ticker":"ASTH","company_name":"Astrana Health, Inc.","filed_at":"2026-06-10T20:15:42+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-06-10","outcome":"passed","proposal_text":"Advisory vote on the compensation program for the Company's named executive officers as disclosed in the Proxy Statement.","proposal_type":"say_on_pay","results":[{"broker_non_votes":"8,356,118","subject":null,"votes_abstain":"88,206","votes_against":"1,209,072","votes_for":"34,119,199","votes_withheld":null}]},"claim":"Astrana Health, Inc. shareholders approved Advisory vote on the compensation program for the Company's named executive officers as disclosed in the Proxy Statement. at the 2026-06-10 meeting.","evidence_excerpt":"3. The compensation program for the Company’s named executive officers as disclosed in Proxy Statement was approved, on an advisory, non-binding basis.","confidence":0.99,"filing_url":"https://secwatch.observer/filing/0001104659-26-072343","anchor_url":"https://secwatch.observer/filing/0001104659-26-072343#claim-b46410f7c855fe5975ef3638942e2f37d5f13b31","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1083446/000110465926072343/0001104659-26-072343-index.htm"},{"fact_type":"shareholder_vote","fact_key":"ef640ffce4b6595ec9460f35206796a6f06fd7c7","cik":1083446,"ticker":"ASTH","company_name":"Astrana Health, Inc.","filed_at":"2026-06-10T20:15:42+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-06-10","outcome":"passed","proposal_text":"Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.","proposal_type":"auditor_ratification","results":[{"broker_non_votes":"0","subject":null,"votes_abstain":"30,520","votes_against":"19,566","votes_for":"43,722,509","votes_withheld":null}]},"claim":"Astrana Health, Inc. shareholders approved Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. at the 2026-06-10 meeting.","evidence_excerpt":"2. The appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified.","confidence":0.99,"filing_url":"https://secwatch.observer/filing/0001104659-26-072343","anchor_url":"https://secwatch.observer/filing/0001104659-26-072343#claim-ef640ffce4b6595ec9460f35206796a6f06fd7c7","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1083446/000110465926072343/0001104659-26-072343-index.htm"},{"fact_type":"shareholder_vote","fact_key":"14598a9bf6a54f4ead8459bdb2241cd043f84b05","cik":1083446,"ticker":"ASTH","company_name":"Astrana Health, Inc.","filed_at":"2026-06-10T20:15:42+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-06-10","outcome":"passed","proposal_text":"Election of nine directors to the Board, each to hold office until the 2027 Annual Meeting of Stockholders.","proposal_type":"director_election","results":[{"broker_non_votes":"8,356,118","subject":"Kenneth Sim, M.D.","votes_abstain":null,"votes_against":"1,959,958","votes_for":"33,456,519","votes_withheld":null},{"broker_non_votes":"8,356,118","subject":"Thomas S. Lam, M.D., M.P.H.","votes_abstain":null,"votes_against":"1,929,968","votes_for":"33,486,509","votes_withheld":null},{"broker_non_votes":"8,356,118","subject":"John Chiang","votes_abstain":null,"votes_against":"1,312,431","votes_for":"34,104,046","votes_withheld":null},{"broker_non_votes":"8,356,118","subject":"Weili Dai","votes_abstain":null,"votes_against":"1,489,781","votes_for":"33,926,696","votes_withheld":null},{"broker_non_votes":"8,356,118","subject":"Linda Dong","votes_abstain":null,"votes_against":"2,085,836","votes_for":"33,330,641","votes_withheld":null},{"broker_non_votes":"8,356,118","subject":"J. Lorraine Estradas, R.N., B.S.N. M.P.H.","votes_abstain":null,"votes_against":"3,244,703","votes_for":"32,171,774","votes_withheld":null},{"broker_non_votes":"8,356,118","subject":"Mitchell W. Kitayama","votes_abstain":null,"votes_against":"2,095,971","votes_for":"33,320,506","votes_withheld":null},{"broker_non_votes":"8,356,118","subject":"Matthew Mazdyasni","votes_abstain":null,"votes_against":"1,805,688","votes_for":"33,610,789","votes_withheld":null},{"broker_non_votes":"8,356,118","subject":"David G. Schmidt","votes_abstain":null,"votes_against":"2,218,024","votes_for":"33,198,453","votes_withheld":null}]},"claim":"Astrana Health, Inc. shareholders approved Election of nine directors to the Board, each to hold office until the 2027 Annual Meeting of Stockholders. at the 2026-06-10 meeting.","evidence_excerpt":"The voting results for each such matter were as follows: Proposal 1. Election of Directors Nominee For Withheld Broker Non-Votes Kenneth Sim, M.D. 33,456,519 1,959,958 8,356,118 Thomas S. Lam, M.D., M.P.H. 33,486,509 1,929,968 8,356,118 John Chiang 34,104,046 1,312,431 8,356,118 Weili Dai 33,926,696 1,489,781 8,356,118 Linda Dong 33,330,641 2,085,836 8,356,118 J. Lorraine Estradas, R.N., B.S.N. M.P.H. 32,171,774 3,244,703 8,356,118 Mitchell W. Kitayama 33,320,506 2,095,971 8,356,118 Matthew Mazdyasni 33,610,789 1,805,688 8,356,118 David G. Schmidt 33,198,453 2,218,024 8,356,118","confidence":0.99,"filing_url":"https://secwatch.observer/filing/0001104659-26-072343","anchor_url":"https://secwatch.observer/filing/0001104659-26-072343#claim-14598a9bf6a54f4ead8459bdb2241cd043f84b05","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1083446/000110465926072343/0001104659-26-072343-index.htm"},{"fact_type":"executive_change","fact_key":"063e080b66","cik":1083446,"ticker":"ASTH","company_name":"Astrana Health, Inc.","filed_at":"2026-05-12T10:06:08+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2026-06-01","interim":false,"role":"Chief Medical Officer","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Dinesh Kumar, M.D. resigned as Chief Medical Officer at Astrana Health, Inc..","evidence_excerpt":"On May 7, 2026, Dinesh Kumar, M.D., the Chief Medical Officer of Astrana Health, Inc. (the “Company”), notified the Company of his intention to resign, effective as of June 1, 2026.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-26-058922","anchor_url":"https://secwatch.observer/filing/0001104659-26-058922#claim-063e080b66","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1083446/000110465926058922/0001104659-26-058922-index.htm"},{"fact_type":"earnings_release","fact_key":"6b88b6553474132cd69ed162250bd2f98791435d","cik":1083446,"ticker":"ASTH","company_name":"Astrana Health, Inc.","filed_at":"2026-05-07T23:59:59+00:00","payload":{"eps_text":"$0.29","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$14.4 million","period_text":"first quarter ended March 31, 2026","report_date":"2026-05-07","result_type":"reported_results","revenue_text":"$965.1 million"},"claim":"Astrana Health, Inc. reported first quarter ended March 31, 2026 results: revenue $965.1 million, net income $14.4 million, EPS $0.29.","evidence_excerpt":"Financial Highlights for First Quarter Ended March 31, 2026: All comparisons are to the three months ended March 31, 2025 unless otherwise stated. · Total revenue of $965.1 million, up 56% from $620.4 million · Care Partners revenue of $909.7 million, up 51% from $601.0 million · Net income attributable to Astrana of $14.4 million, up 116% from $6.7 million · Earnings per share (“EPS”) - diluted of $0.29, up 107% from $0.14","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-26-057134","anchor_url":"https://secwatch.observer/filing/0001104659-26-057134#claim-6b88b6553474132cd69ed162250bd2f98791435d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1083446/000110465926057134/0001104659-26-057134-index.htm"},{"fact_type":"ma_transaction","fact_key":"eef89f36fd827e4721013a8ee3a6ae6d669c6fe3","cik":1083446,"ticker":"ASTH","company_name":"Astrana Health, Inc.","filed_at":"2025-07-02T23:59:59+00:00","payload":{"action":"acquisition","closing_date":"2025-07-01","consideration_text":"$707.9 million in cash and the assumption of certain identified liabilities","counterparty":"PHP Holdings, LLC","effective_date":"2025-07-01","item_codes_triggered":["2.01"]},"claim":"Astrana Health, Inc. completed an acquisition involving PHP Holdings, LLC for $707.9 million in cash and the assumption of certain identified liabilities (closed 2025-07-01).","evidence_excerpt":"intended to address and reconcile post-Closing claims, matters,\nand obligations between the parties, including a reduction in the aggregate purchase price from $745.0 million to $707.9 million and the\nremoval of certain post-Closing purchase price adjustments and related escrow. The Company and Sellers also entered into certain ancillary\nagreements, including a","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-25-065009","anchor_url":"https://secwatch.observer/filing/0001104659-25-065009#claim-eef89f36fd827e4721013a8ee3a6ae6d669c6fe3","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1083446/000110465925065009/0001104659-25-065009-index.htm"},{"fact_type":"executive_change","fact_key":"b150e7fc42","cik":1083446,"ticker":"ASTH","company_name":"Astrana Health, Inc.","filed_at":"2025-03-28T23:59:59+00:00","payload":{"action":"transitioned","action_category":"role_change","departure_tone":"not_applicable","effective_date":"2025-03-26","interim":false,"role":"Chief Accounting Officer","role_category":"other_named_officer","successor_name":"Glenn W. Sobotka","successor_named":true},"claim":"John Vong changed role as Chief Accounting Officer at Astrana Health, Inc..","evidence_excerpt":"John Vong, the Company’s current Chief Accounting Officer and principal accounting officer, will transition to a new role at the Company and will no longer serve as the principal accounting officer as of the Effective Date.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-25-028969","anchor_url":"https://secwatch.observer/filing/0001104659-25-028969#claim-b150e7fc42","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1083446/000110465925028969/0001104659-25-028969-index.htm"},{"fact_type":"executive_change","fact_key":"4046e637e8","cik":1083446,"ticker":"ASTH","company_name":"Astrana Health, Inc.","filed_at":"2025-03-28T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2025-03-26","interim":false,"role":"Chief Accounting Officer","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Glenn W. Sobotka was appointed as Chief Accounting Officer at Astrana Health, Inc..","evidence_excerpt":"On March 26, 2025, Astrana Health, Inc. (the “Company”) appointed Glenn W. Sobotka as the Company’s Chief Accounting Officer and principal accounting officer, effective March 26, 2025","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-25-028969","anchor_url":"https://secwatch.observer/filing/0001104659-25-028969#claim-4046e637e8","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1083446/000110465925028969/0001104659-25-028969-index.htm"},{"fact_type":"debt_financing","fact_key":"a38e249d4f44fcc1c494e1882ba742a99a04d334","cik":1083446,"ticker":"ASTH","company_name":"Astrana Health, Inc.","filed_at":"2025-02-27T23:59:59+00:00","payload":{"counterparty":"Truist Bank (as administrative agent)","effective_date":"2025-02-26","event":"amendment","instrument_type":"term_loan","interest_rate_text":"term SOFR plus 1.25% to 2.50% or base rate plus 0.25% to 1.50%","item_codes_triggered":["2.03"],"maturity_text":"five years from the closing date","principal_text":"$745,000,000"},"claim":"Astrana Health, Inc. amended term loan of $745,000,000 with Truist Bank (as administrative agent) at term SOFR plus 1.25% to 2.50% or base rate plus 0.25% to 1.50% maturing five years from the closing date.","evidence_excerpt":"(c) a five-year delayed draw term loan credit facility to the Company of $745,000,000","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-25-018221","anchor_url":"https://secwatch.observer/filing/0001104659-25-018221#claim-a38e249d4f44fcc1c494e1882ba742a99a04d334","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1083446/000110465925018221/0001104659-25-018221-index.htm"},{"fact_type":"debt_financing","fact_key":"ff4d2290685833722d88ce58a564144a5a9d6db1","cik":1083446,"ticker":"ASTH","company_name":"Astrana Health, Inc.","filed_at":"2025-02-27T23:59:59+00:00","payload":{"counterparty":"Truist Bank (as administrative agent)","effective_date":"2025-02-26","event":"amendment","instrument_type":"revolving_credit","interest_rate_text":"term SOFR plus 1.25% to 2.50% or base rate plus 0.25% to 1.50%","item_codes_triggered":["2.03"],"maturity_text":"five years from the closing date","principal_text":"$300,000,000"},"claim":"Astrana Health, Inc. amended revolving credit of $300,000,000 with Truist Bank (as administrative agent) at term SOFR plus 1.25% to 2.50% or base rate plus 0.25% to 1.50% maturing five years from the closing date.","evidence_excerpt":"provides for (a) a five-year revolving credit facility to the Company of $300,000,000","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-25-018221","anchor_url":"https://secwatch.observer/filing/0001104659-25-018221#claim-ff4d2290685833722d88ce58a564144a5a9d6db1","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1083446/000110465925018221/0001104659-25-018221-index.htm"},{"fact_type":"earnings_release","fact_key":"12cb6f28afdac9312589f0ffea17c466e7e68969","cik":1083446,"ticker":"ASTH","company_name":"Astrana Health, Inc.","filed_at":"2024-05-07T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"reaffirmed","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"first quarter ended March 31, 2024","report_date":"2024-05-07","result_type":"reported_results","revenue_text":null},"claim":"Astrana Health, Inc. updated its first quarter ended March 31, 2024 guidance (reaffirmed).","evidence_excerpt":"On May 7, 2024, Astrana Health, Inc. (the \"Company\") issued a press release announcing its financial results for the three months ended March 31, 2024. A copy of the press release and supplemental data is furnished with this Current Report on Form 8-K as Exhibit 99.1 and Exhibit 99.2, respectively, and incorporated herein by reference.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-24-058018","anchor_url":"https://secwatch.observer/filing/0001104659-24-058018#claim-12cb6f28afdac9312589f0ffea17c466e7e68969","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1083446/000110465924058018/0001104659-24-058018-index.htm"},{"fact_type":"governance_change","fact_key":"8bb30b601b01e5943d8c8272856b9a811254875a","cik":1083446,"ticker":"ASTH","company_name":"Astrana Health, Inc.","filed_at":"2024-04-24T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2024-04-24","item_codes_triggered":["5.03"],"summary_text":"Eliminated all matters related to Series A and Series B Convertible Preferred Stock from the Certificate of Incorporation via a Certificate of Elimination, returning these shares to authorized but unissued preferred stock without designation."},"claim":"Astrana Health, Inc.: Eliminated all matters related to Series A and Series B Convertible Preferred Stock from the Certificate of Incorporation via a Certificate of Elimination, returning these shares to authorized but unissued preferred stock without designation (effective 2024-04-24).","evidence_excerpt":"On April 24, 2024, Astrana Health, Inc. (the “Company”) filed a Certificate of Elimination (the “Certificate of Elimination”) to its Restated Certificate of Incorporation (as amended, the “Certificate of Incorporation”) with the Secretary of State of the State of Delaware, eliminating from the Certificate of Incorporation all matters set forth in the Amended and Restated Certificate of Designation with respect to the Company’s Series A Convertible Preferred Stock (the “Series A Preferred Stock”) and Series B Convertible Preferred Stock (the “Series B Preferred Stock”) and returning each of the Series A Preferred Stock and Series B Preferred Stock to the status of authorized and unissued shares of preferred stock of the Company, without designation as to series.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-24-050973","anchor_url":"https://secwatch.observer/filing/0001104659-24-050973#claim-8bb30b601b01e5943d8c8272856b9a811254875a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1083446/000110465924050973/0001104659-24-050973-index.htm"},{"fact_type":"executive_change","fact_key":"9d0e40c9cc","cik":1083446,"ticker":"ASTH","company_name":"Astrana Health, Inc.","filed_at":"2024-04-24T23:59:59+00:00","payload":{"action":"transitioned","action_category":"role_change","departure_tone":"not_applicable","effective_date":"2024-04-23","interim":false,"role":"Senior Vice President of Health Affairs","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Dr. Albert Young changed role as Senior Vice President of Health Affairs at Astrana Health, Inc..","evidence_excerpt":"Effective April 23, 2024, Dr. Albert Young transitioned from his position as Chief Administrative Officer of Astrana Health, Inc. (the “Company”) to a new role as Senior Vice President of Health Affairs of the Company.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-24-050759","anchor_url":"https://secwatch.observer/filing/0001104659-24-050759#claim-9d0e40c9cc","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1083446/000110465924050759/0001104659-24-050759-index.htm"},{"fact_type":"governance_change","fact_key":"0965487b5d4b87a3efbc127b3736197d3961cd1a","cik":1083446,"ticker":"ASTH","company_name":"Astrana Health, Inc.","filed_at":"2024-02-29T23:59:59+00:00","payload":{"change_type":"bylaw_amendment","effective_date":"2024-02-28","item_codes_triggered":["5.03"],"summary_text":"Amended and Restated Bylaws approved, adding procedural mechanics for stockholder nominations, universal proxy rules, white proxy card reservation, and updates for Delaware law compliance."},"claim":"Astrana Health, Inc.: Amended and Restated Bylaws approved, adding procedural mechanics for stockholder nominations, universal proxy rules, white proxy card reservation, and updates for Delaware law compliance (effective 2024-02-28).","evidence_excerpt":"On February 28, 2024, the Board of Directors (the “Board”) of Astrana Health, Inc. (the “Company”) approved the amendment and restatement of the Company’s Restated Bylaws (as amended and restated, the “Amended and Restated Bylaws”), which became effective immediately upon adoption.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-24-028972","anchor_url":"https://secwatch.observer/filing/0001104659-24-028972#claim-0965487b5d4b87a3efbc127b3736197d3961cd1a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1083446/000110465924028972/0001104659-24-028972-index.htm"},{"fact_type":"earnings_release","fact_key":"a50a506057ff0d3d9dab0cae7aa94298d8458e58","cik":1083446,"ticker":"ASTH","company_name":"Astrana Health, Inc.","filed_at":"2024-02-27T23:59:59+00:00","payload":{"eps_text":"$1.29","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$60.7 million","period_text":"three and twelve months ended December 31, 2023","report_date":"2024-02-27","result_type":"reported_results","revenue_text":"$1,386.7 million"},"claim":"Astrana Health, Inc. reported three and twelve months ended December 31, 2023 results: revenue $1,386.7 million, net income $60.7 million, EPS $1.29.","evidence_excerpt":"of Astrana Health. Financial Highlights for the Year Ended December 31,\n2023: All comparisons are to year ended December\n31, 2022 unless otherwise stated. • Total revenue of $1,386.7 million,\n up 21% from $1,144.2 million • Care Partners revenue of $1,300.1\n million, up 24% from $1,051.5 million • Net income attributable to Astrana\n of $60.7 million, up 34% from","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-24-028213","anchor_url":"https://secwatch.observer/filing/0001104659-24-028213#claim-a50a506057ff0d3d9dab0cae7aa94298d8458e58","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1083446/000110465924028213/0001104659-24-028213-index.htm"},{"fact_type":"governance_change","fact_key":"4d1c1bc71c375b9df5158fd4458b7e4246a51720","cik":1083446,"ticker":"ASTH","company_name":"Astrana Health, Inc.","filed_at":"2024-02-26T23:59:59+00:00","payload":{"change_type":"bylaw_amendment","effective_date":"2024-02-26","item_codes_triggered":["5.03"],"summary_text":"Amended and restated by-laws to reflect name change and incorporate all prior amendments."},"claim":"Astrana Health, Inc.: Amended and restated by-laws to reflect name change and incorporate all prior amendments (effective 2024-02-26).","evidence_excerpt":"effective February 26, 2024, the Company’s By-Laws were amended and restated to reflect the Name Change and incorporate all prior amendments to the By-Laws.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-24-027198","anchor_url":"https://secwatch.observer/filing/0001104659-24-027198#claim-4d1c1bc71c375b9df5158fd4458b7e4246a51720","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1083446/000110465924027198/0001104659-24-027198-index.htm"},{"fact_type":"governance_change","fact_key":"099103211c1fdc0174198ba6649fc91fcef5e449","cik":1083446,"ticker":"ASTH","company_name":"Astrana Health, Inc.","filed_at":"2024-02-26T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2024-02-26","item_codes_triggered":["5.03"],"summary_text":"Amended certificate of incorporation to change corporate name from Apollo Medical Holdings, Inc. to Astrana Health, Inc."},"claim":"Astrana Health, Inc.: Amended certificate of incorporation to change corporate name from Apollo Medical Holdings, Inc. to Astrana Health, Inc (effective 2024-02-26).","evidence_excerpt":"on January 25, 2024, Astrana Health, Inc. (the “Company”) filed a Certificate of Amendment to the Company’s Restated Certificate of Incorporation with the Secretary of State of the State of Delaware to effect a change in corporate name from “Apollo Medical Holdings, Inc.” to “Astrana Health, Inc.” (the “Name Change”). The Name Change became effective as of 12:01 a.m. Eastern Time on February 26, 2024.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-24-027198","anchor_url":"https://secwatch.observer/filing/0001104659-24-027198#claim-099103211c1fdc0174198ba6649fc91fcef5e449","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1083446/000110465924027198/0001104659-24-027198-index.htm"},{"fact_type":"governance_change","fact_key":"4e839d06cb8aaa105b734e9e6605614573fb23e3","cik":1083446,"ticker":"ASTH","company_name":"Astrana Health, Inc.","filed_at":"2024-01-26T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2024-02-26","item_codes_triggered":["5.03"],"summary_text":"Changed corporate name from Apollo Medical Holdings, Inc. to Astrana Health, Inc."},"claim":"Astrana Health, Inc.: Changed corporate name from Apollo Medical Holdings, Inc. to Astrana Health, Inc (effective 2024-02-26).","evidence_excerpt":"On January 25, 2024, the Company filed a Certificate of Amendment to the Company's Restated Certificate of Incorporation (the “Amendment”) with the Secretary of State of the State of Delaware to change its corporate name from “Apollo Medical Holdings, Inc.” to “Astrana Health, Inc.”, effective as of 12:01 a.m. Eastern Time on February 26, 2024 (the “Name Change”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-24-006988","anchor_url":"https://secwatch.observer/filing/0001104659-24-006988#claim-4e839d06cb8aaa105b734e9e6605614573fb23e3","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1083446/000110465924006988/0001104659-24-006988-index.htm"},{"fact_type":"executive_change","fact_key":"3b0e554f23","cik":1083446,"ticker":"ASTH","company_name":"Astrana Health, Inc.","filed_at":"2024-01-24T23:59:59+00:00","payload":{"action":"appointed","action_category":"role_change","departure_tone":"not_applicable","effective_date":"2024-01-19","interim":false,"role":"Chief Financial Officer and Chief Operating Officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Chandan Basho was appointed as Chief Financial Officer and Chief Operating Officer at Astrana Health, Inc..","evidence_excerpt":"· Chandan Basho, previously Chief Financial Officer and Chief Strategy Officer, was appointed Chief Financial Officer and Chief Operating Officer.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-24-006114","anchor_url":"https://secwatch.observer/filing/0001104659-24-006114#claim-3b0e554f23","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1083446/000110465924006114/0001104659-24-006114-index.htm"},{"fact_type":"executive_change","fact_key":"fe8dda086a","cik":1083446,"ticker":"ASTH","company_name":"Astrana Health, Inc.","filed_at":"2024-01-24T23:59:59+00:00","payload":{"action":"appointed","action_category":"role_change","departure_tone":"not_applicable","effective_date":"2024-01-19","interim":false,"role":"Chief Executive Officer and President","role_category":"ceo","successor_name":null,"successor_named":false},"claim":"Brandon Sim was appointed as Chief Executive Officer and President at Astrana Health, Inc..","evidence_excerpt":"· Brandon Sim, previously Co-Chief Executive Officer, was appointed Chief Executive Officer and President;","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-24-006114","anchor_url":"https://secwatch.observer/filing/0001104659-24-006114#claim-fe8dda086a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1083446/000110465924006114/0001104659-24-006114-index.htm"},{"fact_type":"executive_change","fact_key":"61d86d23d7","cik":1083446,"ticker":"ASTH","company_name":"Astrana Health, Inc.","filed_at":"2024-01-24T23:59:59+00:00","payload":{"action":"appointed","action_category":"role_change","departure_tone":"not_applicable","effective_date":"2024-01-19","interim":false,"role":"Vice Chairman of the Board","role_category":"other","successor_name":null,"successor_named":false},"claim":"Thomas S. Lam was appointed as Vice Chairman of the Board at Astrana Health, Inc..","evidence_excerpt":"· Thomas S. Lam, M.D., M.P.H., previously Co-Chief Executive Officer and President and a director, was appointed Vice Chairman of the Board;","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-24-006114","anchor_url":"https://secwatch.observer/filing/0001104659-24-006114#claim-61d86d23d7","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1083446/000110465924006114/0001104659-24-006114-index.htm"},{"fact_type":"earnings_release","fact_key":"6d108d5eabc0f85bf92aa5a41b4e3ef5ded75fa4","cik":1083446,"ticker":"ASTH","company_name":"Astrana Health, Inc.","filed_at":"2023-11-07T23:59:59+00:00","payload":{"eps_text":"$0.47","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$22.1 million","period_text":"third quarter ended September 30, 2023","report_date":"2023-11-07","result_type":"reported_results","revenue_text":"$348.2 million"},"claim":"Astrana Health, Inc. reported third quarter ended September 30, 2023 results: revenue $348.2 million, net income $22.1 million, EPS $0.47.","evidence_excerpt":"ahead.” Financial Highlights for Third Quarter Ended\nSeptember 30, 2023: All comparisons are to the quarter ended September 30,\n2022 unless otherwise stated. · Total revenue of $348.2 million,\n up 10% from $317.0 million · Care Partners revenue of $326.5 million,\n up 11% from $293.6 million · Net income attributable to ApolloMed\n of $22.1 million, compared to $23.2","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-23-115263","anchor_url":"https://secwatch.observer/filing/0001104659-23-115263#claim-6d108d5eabc0f85bf92aa5a41b4e3ef5ded75fa4","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1083446/000110465923115263/0001104659-23-115263-index.htm"},{"fact_type":"debt_financing","fact_key":"437c79e2f6949cf8d18ce8793e69c35080e91247","cik":1083446,"ticker":"ASTH","company_name":"Astrana Health, Inc.","filed_at":"2023-11-07T23:59:59+00:00","payload":{"counterparty":"Truist Bank","effective_date":"2023-11-03","event":"amendment","instrument_type":"credit_facility","interest_rate_text":"subject to a spread based on the Company's leverage ratio","item_codes_triggered":["2.03"],"maturity_text":"June 16, 2026","principal_text":"$400.0 million"},"claim":"Astrana Health, Inc. amended credit facility of $400.0 million with Truist Bank at subject to a spread based on the Company's leverage ratio maturing June 16, 2026.","evidence_excerpt":"The Credit Agreement Amendment does not change the amount of the Revolving Line of Credit (which remains at $400.0 million), the maturity date of the Revolving Line of Credit (which remains June 16, 2026), or the rate of interest paid on the Revolving Line of Credit (which remains subject to a spread based on the Company's leverage ratio).","confidence":0.4,"filing_url":"https://secwatch.observer/filing/0001104659-23-115255","anchor_url":"https://secwatch.observer/filing/0001104659-23-115255#claim-437c79e2f6949cf8d18ce8793e69c35080e91247","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1083446/000110465923115255/0001104659-23-115255-index.htm"},{"fact_type":"debt_financing","fact_key":"9ca6629e0eaf7b25a7ef7d99c948061eb53e55ea","cik":1083446,"ticker":"ASTH","company_name":"Astrana Health, Inc.","filed_at":"2023-11-07T23:59:59+00:00","payload":{"counterparty":"Truist Bank","effective_date":"2023-11-03","event":"incurrence","instrument_type":"term_loan","interest_rate_text":"Term SOFR Reference Rate plus a spread from 1.50% to 2.75%","item_codes_triggered":["2.03"],"maturity_text":"November 3, 2028","principal_text":"up to $300.0 million, with $180.0 million funded at the closing"},"claim":"Astrana Health, Inc. incurred term loan of up to $300.0 million, with $180.0 million funded at the closing with Truist Bank at Term SOFR Reference Rate plus a spread from 1.50% to 2.75% maturing November 3, 2028.","evidence_excerpt":"The Credit Agreement Amendment provides a new term loan to the Company in an aggregate amount of up to $300.0 million, with $180.0 million funded at the closing of the Credit Agreement Amendment, and $120.0 million available to be drawn by the Company as delayed draw loans during the six months subsequent to the closing of the Credit Agreement Amendment (collectively, the \"New Term Loan\").","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-23-115255","anchor_url":"https://secwatch.observer/filing/0001104659-23-115255#claim-9ca6629e0eaf7b25a7ef7d99c948061eb53e55ea","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1083446/000110465923115255/0001104659-23-115255-index.htm"},{"fact_type":"material_agreement","fact_key":"27fbd8a9a2b36357185ec7edb1b3cc68d7a57901","cik":1083446,"ticker":"ASTH","company_name":"Astrana Health, Inc.","filed_at":"2023-11-07T23:59:59+00:00","payload":{"action":"amendment","agreement_name":"Third Amendment to Amended and Restated Credit Agreement and Incremental Agreement","agreement_type":"credit_facility","counterparty":"Truist Bank, as administrative agent, and the banks and other financial institutions party thereto","effective_date":"2023-11-03","item_codes_triggered":["1.01"],"value_text":"$300.0 million, with $180.0 million funded at the closing"},"claim":"Astrana Health, Inc. amended Third Amendment to Amended and Restated Credit Agreement and Incremental Agreement with Truist Bank, as administrative agent, and the banks and other financial institutions party thereto valued at $300.0 million, with $180.0 million funded at the closing (effective 2023-11-03).","evidence_excerpt":"On November 3, 2023, Apollo Medical Holdings, Inc. (the “Company”) entered into a Third Amendment to Amended and Restated Credit Agreement and Incremental Agreement (the “Credit Agreement Amendment”) with the banks and other financial institutions party thereto and Truist Bank, as administrative agent (the “Administrative Agent”), which amends the Amended and Restated Credit Agreement, dated as of June 16, 2021, entered into among the Company, the lenders party thereto and the Administrative Agent (as amended, the “Credit Agreement”). The Credit Agreement Amendment provides a new term loan to the Company in an aggregate amount of up to $300.0 million, with $180.0 million funded at the closing of the Credit Agreement Amendment","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-23-115255","anchor_url":"https://secwatch.observer/filing/0001104659-23-115255#claim-27fbd8a9a2b36357185ec7edb1b3cc68d7a57901","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1083446/000110465923115255/0001104659-23-115255-index.htm"},{"fact_type":"material_agreement","fact_key":"7efbd2caca4b7f2c50dc87abfd88080d82cbbef7","cik":1083446,"ticker":"ASTH","company_name":"Astrana Health, Inc.","filed_at":"2023-11-07T23:59:59+00:00","payload":{"action":"entry","agreement_name":"stock repurchase agreement","agreement_type":"equity_purchase","counterparty":"Allied Physicians of California, a Professional Medical Corporation (APC)","effective_date":"2023-11-06","item_codes_triggered":["1.01"],"value_text":"approximately $100 million"},"claim":"Astrana Health, Inc. entered into stock repurchase agreement with Allied Physicians of California, a Professional Medical Corporation (APC) valued at approximately $100 million (effective 2023-11-06).","evidence_excerpt":"On November 6, 2023, Apollo Medical Holdings, Inc. (the “Company”) entered into a stock repurchase agreement with Allied Physicians of California, a Professional Medical Corporation (“APC”), pursuant to which the Company agreed to repurchase approximately $100 million of the Company’s common stock from APC.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-23-115249","anchor_url":"https://secwatch.observer/filing/0001104659-23-115249#claim-7efbd2caca4b7f2c50dc87abfd88080d82cbbef7","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1083446/000110465923115249/0001104659-23-115249-index.htm"},{"fact_type":"material_agreement","fact_key":"23367bd2a450c93f4a92d51592384098a2db6e71","cik":1083446,"ticker":"ASTH","company_name":"Astrana Health, Inc.","filed_at":"2023-11-07T23:59:59+00:00","payload":{"action":"entry","agreement_name":"I Health Purchase Agreement","agreement_type":"equity_purchase","counterparty":"Ronald Brandt and Allison Brandt","effective_date":"2023-11-07","item_codes_triggered":["1.01"],"value_text":null},"claim":"Astrana Health, Inc. entered into I Health Purchase Agreement with Ronald Brandt and Allison Brandt (effective 2023-11-07).","evidence_excerpt":"NMM has entered into a Stock Purchase Agreement, dated November 7, 2023 (the “I Health Purchase Agreement”), with Ronald Brandt and Allison Brandt, each in their individual capacities and in their capacities as Co-Trustees of the Ronald Lee Brandt and Allison Leigh Brandt Family Trust dated December 16, 2003, and I Health, Inc. (“I Health”)","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-23-115243","anchor_url":"https://secwatch.observer/filing/0001104659-23-115243#claim-23367bd2a450c93f4a92d51592384098a2db6e71","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1083446/000110465923115243/0001104659-23-115243-index.htm"},{"fact_type":"material_agreement","fact_key":"d34a486383a50091e5e59884f9623ba550fad76a","cik":1083446,"ticker":"ASTH","company_name":"Astrana Health, Inc.","filed_at":"2023-11-07T23:59:59+00:00","payload":{"action":"entry","agreement_name":"CFC/AHMS Purchase Agreement","agreement_type":"asset_purchase","counterparty":"Community Family Care Medical Group IPA, Inc.","effective_date":"2023-11-07","item_codes_triggered":["1.01"],"value_text":"aggregate purchase price of $113.8 million"},"claim":"Astrana Health, Inc. entered into CFC/AHMS Purchase Agreement with Community Family Care Medical Group IPA, Inc. valued at aggregate purchase price of $113.8 million (effective 2023-11-07).","evidence_excerpt":"entered into an Asset and Equity Purchase Agreement, dated November 7, 2023, with Community Family Care Medical Group IPA, Inc. (“CFC”), Advanced Health Management Systems, L.P. (“AHMS”), Accie M. Mitchell and Gloria C. Mitchell, as Co-Trustees of the Mitchell Family Trust dated July 2, 2003, CFC Management, LLC, the limited partners of AHMS and Marc Mitchell, as the Equityholder Representative (the “CFC/AHMS Purchase Agreement”)","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-23-115243","anchor_url":"https://secwatch.observer/filing/0001104659-23-115243#claim-d34a486383a50091e5e59884f9623ba550fad76a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1083446/000110465923115243/0001104659-23-115243-index.htm"},{"fact_type":"material_agreement","fact_key":"6f5689d53c41ba0b360f658c4390de1939d227ec","cik":1083446,"ticker":"ASTH","company_name":"Astrana Health, Inc.","filed_at":"2023-09-08T23:59:59+00:00","payload":{"action":"amendment","agreement_name":"Second Amendment to Amended and Restated Credit Agreement and Waiver","agreement_type":"credit_facility","counterparty":"Truist Bank","effective_date":"2023-09-08","item_codes_triggered":["1.01"],"value_text":"increased the letter of credit sub-facility from $25.0 million to $50.0 million"},"claim":"Astrana Health, Inc. amended Second Amendment to Amended and Restated Credit Agreement and Waiver with Truist Bank valued at increased the letter of credit sub-facility from $25.0 million to $50.0 million (effective 2023-09-08).","evidence_excerpt":"On September 8, 2023, Apollo Medical Holdings, Inc. (the “Company”) entered into the Second Amendment to Amended and Restated Credit Agreement and Waiver (the “Amendment”) to the Amended and Restated Credit Agreement, dated as of June 16, 2021, by and among the Company, as borrower, the lenders party thereto, and Truist Bank, as administrative agent (as amended, the “Credit Agreement”).","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-23-099360","anchor_url":"https://secwatch.observer/filing/0001104659-23-099360#claim-6f5689d53c41ba0b360f658c4390de1939d227ec","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1083446/000110465923099360/0001104659-23-099360-index.htm"},{"fact_type":"earnings_release","fact_key":"0bb5c12c4d6a7676fafea6a14e3ef693753f85e5","cik":1083446,"ticker":"ASTH","company_name":"Astrana Health, Inc.","filed_at":"2023-08-09T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"reaffirmed","item_codes_triggered":["2.02"],"net_income_text":"$26.3 million","period_text":"six months ended June 30, 2023","report_date":"2023-08-07","result_type":"reported_results","revenue_text":"$685.5 million"},"claim":"Astrana Health, Inc. reported six months ended June 30, 2023 results: revenue $685.5 million, net income $26.3 million. Guidance reaffirmed.","evidence_excerpt":"Financial Highlights for Six Months Ended June 30, 2023: All comparisons are to the six months ended June 30, 2022 unless otherwise stated. • Total revenue of $685.5 million, up 29% from $533.0 million • Care Partners revenue of $639.9 million, up 31% from $488.6 million • Net income attributable to ApolloMed of $26.3 million, up 2% from $25.7 million","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-23-089366","anchor_url":"https://secwatch.observer/filing/0001104659-23-089366#claim-0bb5c12c4d6a7676fafea6a14e3ef693753f85e5","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1083446/000110465923089366/0001104659-23-089366-index.htm"},{"fact_type":"earnings_release","fact_key":"7d7005f3d7f78b20acac25d7af26a813a1c552d4","cik":1083446,"ticker":"ASTH","company_name":"Astrana Health, Inc.","filed_at":"2023-08-09T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"reaffirmed","item_codes_triggered":["2.02"],"net_income_text":"$13.2 million","period_text":"second quarter ended June 30, 2023","report_date":"2023-08-07","result_type":"reported_results","revenue_text":"$348.2 million"},"claim":"Astrana Health, Inc. reported second quarter ended June 30, 2023 results: revenue $348.2 million, net income $13.2 million. Guidance reaffirmed.","evidence_excerpt":"full-year 2023.” Financial Highlights for Second Quarter Ended\nJune 30, 2023: All comparisons are to the quarter ended June\n30, 2022 unless otherwise stated. • Total revenue of $348.2 million,\n up 29% from $269.7 million • Care Partners revenue of $325.2 million,\n up 32% from $247.3 million • Net income attributable to ApolloMed\n of $13.2 million, up 10% from $12.0","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-23-089366","anchor_url":"https://secwatch.observer/filing/0001104659-23-089366#claim-7d7005f3d7f78b20acac25d7af26a813a1c552d4","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1083446/000110465923089366/0001104659-23-089366-index.htm"},{"fact_type":"earnings_release","fact_key":"708c81dceee50690976c9cd22df18239d2950564","cik":1083446,"ticker":"ASTH","company_name":"Astrana Health, Inc.","filed_at":"2023-08-07T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"reaffirmed","item_codes_triggered":["2.02"],"net_income_text":"$13.2 million","period_text":"three and six months ended June 30, 2023","report_date":"2023-08-07","result_type":"reported_results","revenue_text":"$348.2 million"},"claim":"Astrana Health, Inc. reported three and six months ended June 30, 2023 results: revenue $348.2 million, net income $13.2 million. Guidance reaffirmed.","evidence_excerpt":"full-year 2023.” Financial Highlights for Second Quarter Ended\nJune 30, 2023: All comparisons are to the quarter ended June\n30, 2022 unless otherwise stated. • Total revenue of $348.2 million, up 29% from $269.7 million • Care Partners revenue of $325.2 million, up 32% from $247.3 million • Net income attributable to ApolloMed of $13.2 million, up 10% from $12.0","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-23-088428","anchor_url":"https://secwatch.observer/filing/0001104659-23-088428#claim-708c81dceee50690976c9cd22df18239d2950564","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1083446/000110465923088428/0001104659-23-088428-index.htm"},{"fact_type":"auditor_change","fact_key":"9527433345ed3228905fea68cb22716249c29c3b","cik":1083446,"ticker":"ASTH","company_name":"Astrana Health, Inc.","filed_at":"2023-08-07T23:59:59+00:00","payload":{"action":"non_reliance","auditor_name":"Ernst & Young LLP","disagreement_text":null,"effective_date":"2023-08-04","item_codes_triggered":["4.02"],"non_reliance_signal":"restatement","successor_auditor_name":null},"claim":"Astrana Health, Inc. reported that prior financial statements should not be relied upon.","evidence_excerpt":"the Company’s previously issued audited consolidated financial statements as of December 31, 2022 and 2021 and for each of the years ended December 31, 2022, 2021 and 2020, included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 (the “2022 Annual Report”), and the Company’s unaudited consolidated financial statements included in the Quarterly Reports on Form 10-Q for the quarterly 2022 fiscal year periods (the “Historical Quarterly Reports”), as well as the unaudited consolidated financial statements included in the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2023 (the “Q1 Quarterly Report” and, together with the 2022 Annual Report and the Historical Quarterly Reports, the “Reports” and all financial statements included in the Reports, collectively, the “Affected Financials”), should no longer be relied upon due to material unintentional errors related to the Company’s tax provision.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-23-088394","anchor_url":"https://secwatch.observer/filing/0001104659-23-088394#claim-9527433345ed3228905fea68cb22716249c29c3b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1083446/000110465923088394/0001104659-23-088394-index.htm"},{"fact_type":"shareholder_vote","fact_key":"ca3907e22713a7cfd951b023d1458f80207be1ec","cik":1083446,"ticker":"ASTH","company_name":"Astrana Health, Inc.","filed_at":"2023-06-16T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-06-13","outcome":"passed","proposal_text":"Approval of the Apollo Medical Holdings, Inc. Employee Stock Purchase Plan","proposal_type":"equity_plan","results":[{"broker_non_votes":"7,458,026","subject":null,"votes_abstain":"3,016","votes_against":"300,550","votes_for":"37,268,131","votes_withheld":null}]},"claim":"Astrana Health, Inc. shareholders approved Approval of the Apollo Medical Holdings, Inc. Employee Stock Purchase Plan at the 2023-06-13 meeting.","evidence_excerpt":"37,268,131 votes were cast “for” the proposal, 300,550 votes were cast “against” the proposal and 3,016 votes abstained. Additionally, there were 7,458,026 broker non-votes for this proposal.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-23-072288","anchor_url":"https://secwatch.observer/filing/0001104659-23-072288#claim-ca3907e22713a7cfd951b023d1458f80207be1ec","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1083446/000110465923072288/0001104659-23-072288-index.htm"},{"fact_type":"shareholder_vote","fact_key":"0d330ad3af810a7f28541756cba701d8835cc1f6","cik":1083446,"ticker":"ASTH","company_name":"Astrana Health, Inc.","filed_at":"2023-06-16T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-06-13","outcome":"passed","proposal_text":"Advisory vote to approve executive compensation","proposal_type":"say_on_pay","results":[{"broker_non_votes":"7,458,026","subject":null,"votes_abstain":"95,515","votes_against":"16,805,967","votes_for":"20,670,215","votes_withheld":null}]},"claim":"Astrana Health, Inc. shareholders approved Advisory vote to approve executive compensation at the 2023-06-13 meeting.","evidence_excerpt":"20,670,215 votes were cast “for” the proposal, 16,805,967 votes were cast “against” the proposal and 95,515 votes abstained. Additionally, there were 7,458,026 broker non-votes for this proposal.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-23-072288","anchor_url":"https://secwatch.observer/filing/0001104659-23-072288#claim-0d330ad3af810a7f28541756cba701d8835cc1f6","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1083446/000110465923072288/0001104659-23-072288-index.htm"},{"fact_type":"shareholder_vote","fact_key":"aac16d3ec159535f2205ad14d2022ca06dde3a72","cik":1083446,"ticker":"ASTH","company_name":"Astrana Health, Inc.","filed_at":"2023-06-16T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-06-13","outcome":"passed","proposal_text":"Ratification of appointment of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2023","proposal_type":"auditor_ratification","results":[{"broker_non_votes":"0","subject":null,"votes_abstain":"123,617","votes_against":"28,371","votes_for":"44,877,735","votes_withheld":null}]},"claim":"Astrana Health, Inc. shareholders approved Ratification of appointment of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-06-13 meeting.","evidence_excerpt":"44,877,735 votes were cast “for” the ratification, 28,371 votes were cast “against” the ratification and 123,617 votes abstained. There were no broker non-votes for this proposal.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-23-072288","anchor_url":"https://secwatch.observer/filing/0001104659-23-072288#claim-aac16d3ec159535f2205ad14d2022ca06dde3a72","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1083446/000110465923072288/0001104659-23-072288-index.htm"},{"fact_type":"shareholder_vote","fact_key":"4bb47cd756f2332d33aa931601d51cb669edcd38","cik":1083446,"ticker":"ASTH","company_name":"Astrana Health, Inc.","filed_at":"2023-06-16T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-06-13","outcome":"passed","proposal_text":"Election of nine directors to serve until the 2024 Annual Meeting","proposal_type":"director_election","results":[{"broker_non_votes":"7,458,026","subject":"Kenneth Sim, M.D.","votes_abstain":null,"votes_against":null,"votes_for":"36,859,352","votes_withheld":"712,345"},{"broker_non_votes":"7,458,026","subject":"Thomas S. Lam, M.D., M.P.H.","votes_abstain":null,"votes_against":null,"votes_for":"37,208,834","votes_withheld":"362,863"},{"broker_non_votes":"7,458,026","subject":"Mitchell W. Kitayama","votes_abstain":null,"votes_against":null,"votes_for":"35,714,486","votes_withheld":"1,857,211"},{"broker_non_votes":"7,458,026","subject":"David G. Schmidt","votes_abstain":null,"votes_against":null,"votes_for":"36,312,649","votes_withheld":"1,259,048"},{"broker_non_votes":"7,458,026","subject":"Linda Marsh","votes_abstain":null,"votes_against":null,"votes_for":"36,229,555","votes_withheld":"1,342,142"},{"broker_non_votes":"7,458,026","subject":"John Chiang","votes_abstain":null,"votes_against":null,"votes_for":"36,384,534","votes_withheld":"1,187,163"},{"broker_non_votes":"7,458,026","subject":"Matthew Mazdyasni","votes_abstain":null,"votes_against":null,"votes_for":"36,003,599","votes_withheld":"1,568,098"},{"broker_non_votes":"7,458,026","subject":"J. Lorraine Estradas, R.N., B.S.N. M.P.H.","votes_abstain":null,"votes_against":null,"votes_for":"35,536,495","votes_withheld":"2,035,202"},{"broker_non_votes":"7,458,026","subject":"Weili Dai","votes_abstain":null,"votes_against":null,"votes_for":"37,269,055","votes_withheld":"302,642"}]},"claim":"Astrana Health, Inc. shareholders approved Election of nine directors to serve until the 2024 Annual Meeting at the 2023-06-13 meeting.","evidence_excerpt":"The Company’s stockholders elected, by the votes indicated below, nine persons to serve as directors of the Company until its 2024 Annual Meeting of Stockholders and until their successors are duly elected and qualified.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-23-072288","anchor_url":"https://secwatch.observer/filing/0001104659-23-072288#claim-4bb47cd756f2332d33aa931601d51cb669edcd38","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1083446/000110465923072288/0001104659-23-072288-index.htm"},{"fact_type":"earnings_release","fact_key":"71b0b3e37f00be7e0298fe0e6eb87529defa413b","cik":1083446,"ticker":"ASTH","company_name":"Astrana Health, Inc.","filed_at":"2023-05-08T23:59:59+00:00","payload":{"eps_text":"$0.31","guidance_signal":"reaffirmed","item_codes_triggered":["2.02"],"net_income_text":"$14.6 million","period_text":"first quarter ended March 31, 2023","report_date":"2023-05-08","result_type":"reported_results","revenue_text":"$337.2 million"},"claim":"Astrana Health, Inc. reported first quarter ended March 31, 2023 results: revenue $337.2 million, net income $14.6 million, EPS $0.31. Guidance reaffirmed.","evidence_excerpt":"Apollo Medical Holdings, Inc. (“ApolloMed,” and together with its subsidiaries and affiliated entities, the “Company”) (NASDAQ: AMEH), a leading physician-centric, technology-powered healthcare company focused on enabling providers in the successful delivery of value-based care, today announced its consolidated financial results for the first quarter ended March 31, 2023. Financial Highlights for First Quarter Ended March 31, 2023: • Total revenue of $337.2 million, up 28% from $263.3 million for the prior-year quarter • Net income attributable to ApolloMed of $14.6 million, up 3% from $14.3 million for the prior-year quarter • Earnings per share - diluted (“EPS - diluted”) of $0.31, compared to $0.31 per share for the prior-year quarter","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001628280-23-016464","anchor_url":"https://secwatch.observer/filing/0001628280-23-016464#claim-71b0b3e37f00be7e0298fe0e6eb87529defa413b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1083446/000162828023016464/0001628280-23-016464-index.htm"},{"fact_type":"executive_change","fact_key":"cb6c8225a7","cik":1083446,"ticker":"ASTH","company_name":"Astrana Health, Inc.","filed_at":"2023-05-08T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2023-05-05","interim":false,"role":"Chief Financial Officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Chan Basho was appointed as Chief Financial Officer at Astrana Health, Inc..","evidence_excerpt":"On May 5, 2023, the Company’s Board of Directors appointed Chan Basho as Chief Financial Officer and principal financial officer.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001628280-23-016464","anchor_url":"https://secwatch.observer/filing/0001628280-23-016464#claim-cb6c8225a7","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1083446/000162828023016464/0001628280-23-016464-index.htm"},{"fact_type":"earnings_release","fact_key":"b1d6394655859626f9752b8310e2ea008a50ca88","cik":1083446,"ticker":"ASTH","company_name":"Astrana Health, Inc.","filed_at":"2023-02-23T23:59:59+00:00","payload":{"eps_text":"$1.08","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$49.0 million","period_text":"the quarter and year ended December 31, 2022","report_date":"2023-02-23","result_type":"reported_results","revenue_text":"$1.14 billion"},"claim":"Astrana Health, Inc. reported the quarter and year ended December 31, 2022 results: revenue $1.14 billion, net income $49.0 million, EPS $1.08.","evidence_excerpt":"• Total revenue of $1.14 billion, an increase of 48% from $773.9 million for the prior year • Net income attributable to ApolloMed of $49.0 million • Earnings per share — diluted (“EPS — diluted”) of $1.08","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001628280-23-004894","anchor_url":"https://secwatch.observer/filing/0001628280-23-004894#claim-b1d6394655859626f9752b8310e2ea008a50ca88","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1083446/000162828023004894/0001628280-23-004894-index.htm"},{"fact_type":"executive_change","fact_key":"ed994ee31b","cik":1083446,"ticker":"ASTH","company_name":"Astrana Health, Inc.","filed_at":"2023-02-08T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2023-02-15","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Michael Eng resigned as Director at Astrana Health, Inc..","evidence_excerpt":"On February 2, 2023, Michael Eng notified the Board of Directors (the “Board”) of Apollo Medical Holdings, Inc. (the “Company”) of his decision to resign as a member of the Board effective as of February 15, 2023.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-23-014510","anchor_url":"https://secwatch.observer/filing/0001104659-23-014510#claim-ed994ee31b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1083446/000110465923014510/0001104659-23-014510-index.htm"},{"fact_type":"executive_change","fact_key":"7f7fd47f55","cik":1083446,"ticker":"ASTH","company_name":"Astrana Health, Inc.","filed_at":"2022-12-05T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2022-11-30","interim":false,"role":"Chief Accounting Officer","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"John Vong was appointed as Chief Accounting Officer at Astrana Health, Inc..","evidence_excerpt":"On November 30, 2022, Apollo Medical Holdings, Inc. (together with its subsidiaries and affiliated entities, “Company”) appointed John Vong as the Company’s Chief Accounting Officer.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001628280-22-031365","anchor_url":"https://secwatch.observer/filing/0001628280-22-031365#claim-7f7fd47f55","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1083446/000162828022031365/0001628280-22-031365-index.htm"},{"fact_type":"shareholder_vote","fact_key":"ee98c4fa929a8b82ba7cd9e8045e532b0f1919da","cik":1083446,"ticker":"ASTH","company_name":"Astrana Health, Inc.","filed_at":"2022-11-14T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2022-06-16","outcome":"passed","proposal_text":"Advisory vote on the preferred frequency of holding future stockholder advisory votes on executive compensation","proposal_type":"say_on_pay_frequency","results":[]},"claim":"Astrana Health, Inc. shareholders approved Advisory vote on the preferred frequency of holding future stockholder advisory votes on executive compensation at the 2022-06-16 meeting.","evidence_excerpt":"disclosing the results of voting at the Company’s 2022 Annual Meeting of Stockholders (the “Annual Meeting”) held on June 16, 2022, including the results from the vote, on a non-binding advisory basis, for the preferred frequency of holding future stockholder advisory votes on the compensation of the Company’s named executive officers being once every year.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-22-117642","anchor_url":"https://secwatch.observer/filing/0001104659-22-117642#claim-ee98c4fa929a8b82ba7cd9e8045e532b0f1919da","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1083446/000110465922117642/0001104659-22-117642-index.htm"},{"fact_type":"earnings_release","fact_key":"4f24d0b6405ab4642fb61fc94ebdf043a77b0fdf","cik":1083446,"ticker":"ASTH","company_name":"Astrana Health, Inc.","filed_at":"2022-11-03T23:59:59+00:00","payload":{"eps_text":"$1.12","guidance_signal":"raised","item_codes_triggered":["2.02"],"net_income_text":"$51.6 million","period_text":"nine months ended September 30, 2022","report_date":"2022-11-03","result_type":"reported_results","revenue_text":"$850.0 million"},"claim":"Astrana Health, Inc. reported nine months ended September 30, 2022 results: revenue $850.0 million, net income $51.6 million, EPS $1.12. Guidance raised.","evidence_excerpt":"losses from recently acquired IPAs, which it believes to be more reflective of its business. Financial Highlights for Nine Months Ended September 30, 2022: • Total revenue of $850.0 million, up 47% from $578.8 million for the prior-year period • Net income attributable to ApolloMed of $51.6 million, compared to $60.1 million for the prior-year period • EPS-diluted","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001628280-22-028272","anchor_url":"https://secwatch.observer/filing/0001628280-22-028272#claim-4f24d0b6405ab4642fb61fc94ebdf043a77b0fdf","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1083446/000162828022028272/0001628280-22-028272-index.htm"},{"fact_type":"earnings_release","fact_key":"9919c1139f4b52a7a5018ccb4e9932b6062ab88a","cik":1083446,"ticker":"ASTH","company_name":"Astrana Health, Inc.","filed_at":"2022-11-03T23:59:59+00:00","payload":{"eps_text":"$0.56","guidance_signal":"raised","item_codes_triggered":["2.02"],"net_income_text":"$26.0 million","period_text":"quarter ended September 30, 2022","report_date":"2022-11-03","result_type":"reported_results","revenue_text":"$317.0 million"},"claim":"Astrana Health, Inc. reported quarter ended September 30, 2022 results: revenue $317.0 million, net income $26.0 million, EPS $0.56. Guidance raised.","evidence_excerpt":"financial results for the third quarter and nine months ended September 30, 2022. Financial Highlights for Third Quarter Ended September 30, 2022: • Total revenue of $317.0 million, up 40% from $227.1 million for the prior-year quarter • Net income attributable to ApolloMed of $26.0 million, compared to $34.3 million for the prior-year quarter • Earnings","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001628280-22-028272","anchor_url":"https://secwatch.observer/filing/0001628280-22-028272#claim-9919c1139f4b52a7a5018ccb4e9932b6062ab88a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1083446/000162828022028272/0001628280-22-028272-index.htm"},{"fact_type":"executive_change","fact_key":"bf109a46d1","cik":1083446,"ticker":"ASTH","company_name":"Astrana Health, Inc.","filed_at":"2022-05-05T23:59:59+00:00","payload":{"action":"stepped down","action_category":"departure","departure_tone":"routine","effective_date":"2022-05-05","interim":false,"role":"Chief Financial Officer","role_category":"cfo","successor_name":"Chan Basho","successor_named":true},"claim":"Eric Chin departed as Chief Financial Officer at Astrana Health, Inc..","evidence_excerpt":"In connection with the appointment, Eric Chin will step down for personal reasons as Chief Financial Officer effective May 5, 2022.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001628280-22-012666","anchor_url":"https://secwatch.observer/filing/0001628280-22-012666#claim-bf109a46d1","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1083446/000162828022012666/0001628280-22-012666-index.htm"},{"fact_type":"executive_change","fact_key":"e6002aa523","cik":1083446,"ticker":"ASTH","company_name":"Astrana Health, Inc.","filed_at":"2022-05-05T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2022-05-05","interim":true,"role":"Interim Chief Financial Officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Chan Basho was appointed as Interim Chief Financial Officer at Astrana Health, Inc..","evidence_excerpt":"On May 5, 2022, the Company appointed Chan Basho as the Company's Interim Chief Financial Officer, effective May 5, 2022.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001628280-22-012666","anchor_url":"https://secwatch.observer/filing/0001628280-22-012666#claim-e6002aa523","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1083446/000162828022012666/0001628280-22-012666-index.htm"},{"fact_type":"executive_change","fact_key":"3e70e58d1b","cik":1083446,"ticker":"ASTH","company_name":"Astrana Health, Inc.","filed_at":"2022-01-18T23:59:59+00:00","payload":{"action":"retired","action_category":"departure","departure_tone":"retirement","effective_date":"2022-01-12","interim":false,"role":"member of the Board of Directors","role_category":"director","successor_name":null,"successor_named":false},"claim":"Li Yu retired as member of the Board of Directors at Astrana Health, Inc..","evidence_excerpt":"Li Yu, a member of the Board of Directors (the “Board”) of Apollo Medical Holdings, Inc. (the “Company”), has retired from the Board, effective January 12, 2022.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001628280-22-001037","anchor_url":"https://secwatch.observer/filing/0001628280-22-001037#claim-3e70e58d1b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1083446/000162828022001037/0001628280-22-001037-index.htm"},{"fact_type":"executive_change","fact_key":"41be94184e","cik":1083446,"ticker":"ASTH","company_name":"Astrana Health, Inc.","filed_at":"2021-12-20T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2021-12-31","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"J. Lorraine Estradas was appointed as Director at Astrana Health, Inc..","evidence_excerpt":"On December 19, 2021, the Board of Directors (the “Board”) of Apollo Medical Holdings, Inc. (the “Company”) appointed Weili Dai and J. Lorraine Estradas, R.N., B.S.N., M.P.H. to serve as members of the Board, effective December 31, 2021.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-21-151691","anchor_url":"https://secwatch.observer/filing/0001104659-21-151691#claim-41be94184e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1083446/000110465921151691/0001104659-21-151691-index.htm"},{"fact_type":"executive_change","fact_key":"0f5650e5ec","cik":1083446,"ticker":"ASTH","company_name":"Astrana Health, Inc.","filed_at":"2021-12-20T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2021-12-31","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Weili Dai was appointed as Director at Astrana Health, Inc..","evidence_excerpt":"On December 19, 2021, the Board of Directors (the “Board”) of Apollo Medical Holdings, Inc. (the “Company”) appointed Weili Dai and J. Lorraine Estradas, R.N., B.S.N., M.P.H. to serve as members of the Board, effective December 31, 2021.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-21-151691","anchor_url":"https://secwatch.observer/filing/0001104659-21-151691#claim-0f5650e5ec","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1083446/000110465921151691/0001104659-21-151691-index.htm"},{"fact_type":"executive_change","fact_key":"b454e23a4b","cik":1083446,"ticker":"ASTH","company_name":"Astrana Health, Inc.","filed_at":"2021-11-04T23:59:59+00:00","payload":{"action":"stepped down","action_category":"role_change","departure_tone":"not_applicable","effective_date":"2021-11-02","interim":false,"role":"Executive Chairman","role_category":"chair","successor_name":"Brandon Sim","successor_named":true},"claim":"Kenneth Sim changed role as Executive Chairman at Astrana Health, Inc..","evidence_excerpt":"In connection with Brandon Sim’s appointment, Kenneth Sim, M.D. will step out of his current role as Co-Chief Executive Officer. He will continue to serve as the Company’s Executive Chairman.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001628280-21-021770","anchor_url":"https://secwatch.observer/filing/0001628280-21-021770#claim-b454e23a4b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1083446/000162828021021770/0001628280-21-021770-index.htm"},{"fact_type":"executive_change","fact_key":"f453df2f86","cik":1083446,"ticker":"ASTH","company_name":"Astrana Health, Inc.","filed_at":"2021-11-04T23:59:59+00:00","payload":{"action":"appointed","action_category":"role_change","departure_tone":"not_applicable","effective_date":"2021-11-02","interim":false,"role":"Co-Chief Executive Officer","role_category":"ceo","successor_name":null,"successor_named":false},"claim":"Brandon Sim was appointed as Co-Chief Executive Officer at Astrana Health, Inc..","evidence_excerpt":"On November 2, 2021, the Company appointed Brandon Sim as the Company’s Co-Chief Executive Officer.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001628280-21-021770","anchor_url":"https://secwatch.observer/filing/0001628280-21-021770#claim-f453df2f86","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1083446/000162828021021770/0001628280-21-021770-index.htm"}]}